Evans T R J, Keith W N
Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research, UK Beatson Laboratories, Glasgow, UK.
Minerva Ginecol. 2004 Dec;56(6):529-38.
Rapid advances in our understanding of the molecular basis of cancer development and progression over the past 3 decades have led to the design of new potential cancer therapies based on the expression of introduced genes into a tumor or its host. In an attempt to overcome the limitations of direct intratumoral administration of genetic therapies in patients with advanced malignant disease, loco-regional routes of delivery have been explored including the intraperitoneal route. This review highlights the potential of replication-competent oncolytic viruses, virus-mediated gene replacement, and gene-directed enzyme-prodrug strategies, as novel cancer therapies. The potential of exploiting the selectivity of the telomerase gene within cancer cells to develop gene therapy strategies is discussed and the promises and pitfalls in translating these novel therapeutics from the laboratory to the clinic are reviewed.
在过去30年里，我们对癌症发生和发展分子基础的理解取得了飞速进展，这促使人们基于向肿瘤或其宿主导入基因的表达情况，设计出了新的潜在癌症治疗方法。为了克服晚期恶性疾病患者直接瘤内给予基因治疗的局限性，人们探索了包括腹腔内途径在内的局部区域给药途径。本综述重点介绍了具有复制能力的溶瘤病毒、病毒介导的基因替代以及基因导向酶-前药策略作为新型癌症治疗方法的潜力。讨论了利用癌细胞中端粒酶基因的选择性来开发基因治疗策略的潜力，并综述了将这些新型疗法从实验室转化到临床过程中的前景与陷阱。
